Please assess the completion status of the following clinical trial:

Trial Title: Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic evidence of an anaplastic oligodendroglioma. For this study, World Health Organization classification criteria will be used. Central pathology review must take place prior to high-dose therapy but need not occur prior to study entry and induction therapy.~* Pathologic evidence of an anaplastic mixed glioma (i.e. oligoastrocytoma). Again, histopathologic diagnosis will be made using World Health Organization classification criteria. To qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element. Central pathology review must take place prior to high-dose therapy but need not occur in advance of enrollment or induction therapy.~* The diagnostic surgical procedure may have been a complete resection, partial resection, or biopsy.~* Karnofsky performance status \> or equal to 60.~* Granulocyte count \> or equal to 1.5 X 109/L.~* Platelet count \> or equal to 100 X 109/L~* SGOT \< than or equal to 2X upper limit of normal.~* Serum creatinine \< than or equal to 1.5X upper limit of normal~* Bilirubin \< than or equal to 1.5X upper limit of normal~* All patients must sign written informed consent.~Exclusion Criteria:~* Systemic or leptomeningeal metastases (excluding contiguous leptomeninges)~* Prior cranial radiotherapy or systemic chemotherapy~* Other concurrent malignancy (with the exception of cervical carcinoma in situ or basal cell carcinoma of the skin) or serious illness if this would interfere with the prescribed treatment.~* Pregnant or lactating women~* Refusal to use effective contraception

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): temozolomide followed by high dose busulfan and thiotepa

Based on this trial design, predict the completion outcome and termination type (if applicable).